Skip to content
Clinical Trials – home
Not yet recruitingRare disease

Long‑term safety and tolerability of asedebart (AG13909) in patients with congenital adrenal hyperplasia

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial involves individuals with classic congenital adrenal hyperplasia, a rare inherited condition in which the adrenal glands do not produce enough hormones, leading to hormone imbalance. The investigational medicine being studied is Asedebart, also known by the code name Lu AG13909. The drug is given as a solution for injection that is administered subcutaneous, meaning it is placed just under the skin.

The purpose of the study is to evaluate the safety and tolerability of long‑term treatment with Asedebart in participants with classic congenital adrenal hyperplasia. Safety is monitored by recording any side effects that appear during treatment. Blood samples are taken periodically to see how the medicine is processed in the body and how it changes hormone levels. The study also checks whether the immune system creates antibodies against the drug, which are called anti‑drug antibodies.

Participants receive the medication at regular intervals over a period of several years, with scheduled clinic visits for injections, blood draws, and routine health checks. The visits allow researchers to track hormone levels, adjust any other hormone medicines if needed, and observe any adverse events. The overall follow‑up continues until the planned end of the study.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessment and Start of Treatment

    After joining the study, you will attend a baseline visit where your health status is recorded and blood samples are taken to establish initial hormone levels.

    During this visit you will receive the first dose of Asedebart, a subcutaneous (under the skin) injection prepared as a solution for injection. The protocol lists the dose as 0 mg; the exact amount and schedule will be administered according to the study plan.

  2. Step 2

    First Subcutaneous Injection

    The initial injection of Asedebart is given under the skin by a trained study staff member.

    The medication is provided in a solution for injection and is administered at the dose specified in the study protocol.

  3. Step 3

    Regular Safety Monitoring and Blood Sampling

    You will return to the study site for regular visits to check for any side effects and to collect blood samples.

    These visits allow the study team to measure hormone concentrations, monitor drug levels in the blood, and test for any immune response to the medication.

  4. Step 4

    12‑Month Evaluation

    At approximately 12 months after the first injection, a detailed assessment is performed.

    Blood samples are taken to evaluate morning concentrations of the hormones A4 and 17‑OHP, and the daily dose of glucocorticoid you are using is recorded.

    Safety and tolerability of the treatment continue to be reviewed.

  5. Step 5

    24‑Month Evaluation

    Around 24 months, another comprehensive evaluation is conducted.

    The same hormone measurements and glucocorticoid dosing information are collected, and ongoing safety monitoring continues.

  6. Step 6

    36‑Month Evaluation and End of Treatment

    At about 36 months, the final study assessment takes place.

    Blood tests again measure A4 and 17‑OHP levels, and the total glucocorticoid dose is documented.

    The long‑term safety and tolerability of Asedebart are summarized, concluding your participation in the extension trial.

Who can join the trial?

6 criteria

  • You have already taken the study drug called as­edebart in a previous trial for congenital adrenal hyperplasia.
  • The doctors decided that the benefits of as­edebart were greater than the risks for you in the earlier trial, and you are expected to continue benefiting from the medication.
  • You are currently taking a daily dose of glucocorticoid (GC) replacement therapy that is adjusted for your body size (your body surface area).
  • You are willing and able to attend all required study visits.
  • You can read and understand the study information and can sign a written informed consent form.
  • If you are a woman who could become pregnant, you must have a negative pregnancy test before joining, and you must either be unable to become pregnant, have a partner who is permanently sterilized, or agree to use a highly effective method of contraception during the study and for about 4.5 months after the last dose of as­edebart. You also must not donate eggs during this period.

Who cannot join the trial?

14 criteria

  • The participant works at the study site, is a close family member of someone who works there, or is a close family member of an employee’s subordinate.
  • The participant is known to be allergic or intolerant to asedebart or any of its inactive ingredients (excipients).
  • The participant has taken any other investigational drug (anything not approved for regular use) within the last 3 months, or within a time period equal to five times the drug’s half‑life (the time it takes for half of the drug to leave the body), whichever is longer.
  • The participant is pregnant, is breastfeeding, plans to become pregnant, or could become pregnant and is not willing to use reliable birth‑control methods.
  • The participant is considered to have a high risk of an adrenal crisis (a sudden, severe shortage of adrenal hormones) based on the doctor’s judgment, such as having many recent adrenal crises or a crisis caused by lowering steroid doses.
  • The participant currently has, or has a history of, substance or alcohol abuse that meets the official diagnostic criteria (DSM‑5).
  • The participant needs regular or long‑term treatment with systemic steroids (strong anti‑inflammatory hormones) for reasons other than the hormone replacement needed for CAH.
  • The participant has a disease or takes medication that the doctor believes could interfere with safety checks, how well the drug works, or the overall conduct of the study.
  • The participant shows any significant abnormal heart test (ECG) results, abnormal vital signs, or other safety concerns at the screening visit that the doctor thinks could put the participant at risk.
  • The participant is judged by the doctor to be unlikely to follow the study rules or is otherwise unsuitable for any reason.
  • The participant is currently taking, or has taken in the past 3 months, any medication that suppresses the immune system (immunosuppressive treatment) except for their normal glucocorticoid (GC) replacement therapy.
  • The participant has had a major loss of blood (such as from surgery, injury, or donating blood) within the 3 months before the first dose of the study drug.
  • The participant has had major surgery (excluding simple laparoscopic procedures like gallbladder or appendix removal) within the 6 months before the first dose of the study drug.
  • The participant has an abnormal heart test (ECG) at screening that the doctor considers clinically important, such as a PR interval longer than 200 ms, a QRS interval longer than 110 ms, or a corrected QT interval (QTcF) longer than 450 ms (QTcF is calculated using the Fridericia correction method: QTcF = QT divided by RR to the power of 0.33). The test may be repeated once if needed.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Asedebart

    is an experimental medicine being tested in people with classic congenital adrenal hyperplasia. It is provided as a liquid that is injected under the skin. The trial is looking at how safe it is when used for a long time and whether patients can tolerate it well.

  • AG13909

    is the same investigational product but is given as a liquid that is infused into a vein. Like Asedebart, it is being studied in participants with congenital adrenal hyperplasia to see if it is safe and well‑tolerated over an extended period.

What is already known about the treatment

  • Asedebart

    This medication is given as a subcutaneous injection in a liquid solution. It is still an experimental drug being studied in clinical trials and has not yet received market approval. It is being tested to treat classic congenital adrenal hyperplasia, a rare condition where the adrenal glands make too many hormones. It works by blocking a key enzyme that makes excess steroid hormones, placing it in the class of steroidogenesis inhibitors and it is designated as an orphan drug.

  • AG13909

    This medication is delivered intravenously as a solution for infusion. Like Asedebart, it is an investigational product that has not been approved for general medical use. It is also aimed at treating classic congenital adrenal hyperplasia. Its action is to inhibit the same hormone‑producing enzyme, classifying it as a steroidogenesis inhibitor and an orphan drug.

Investigated diseases

congenital adrenal hyperplasia - Congenital adrenal hyperplasia is a genetic condition that affects the adrenal glands' ability to make certain hormones. The most common form reduces production of cortisol and sometimes aldosterone, while causing excess production of male sex hormones. Symptoms often appear in infancy with salt loss, low blood pressure, and abnormal genital development, and can continue with rapid growth and early puberty. If the hormone imbalance is not corrected, the condition can lead to ongoing metabolic disturbances and changes in body composition over time.
Trial detailsLast updated 20 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-525325-20-00Protocol codeCAHdence; 21540AEstimated enrolment35 patientsSponsorH. Lundbeck A/S

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.